Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for <i>IDH</i>-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort
Vincent Esteyrie(Institut Claudius Regaud), Pola Network(Institut Claudius Regaud), E. Martin(Institut de Cancérologie de l'Ouest), Elizabeth Cohen‐Jonathan Moyal(Inserm), François Ducray(Centre National pour la Recherche Scientifique et Technique (CNRST)), Charlotte Bronniman(Centre Hospitalier Universitaire de Bordeaux), Delphine Larrieu‐Ciron(Institut Claudius Regaud), Emmanuelle Uro‐Coste(Institut universitaire du cancer de Toulouse Oncopole), Damien Pouessel(Institut Claudius Regaud), Dominique Figarella‐Branger(Hôpital de la Timone), Alain Carpentier(Hôpital Saint-Louis), Caroline Dehais(Centre National de la Recherche Scientifique)
Cited by 21
Related Papers
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
|Journal of Clinical Oncology|2021|530
Continuous growth of mean tumor diameter in a subset of grade II gliomas
|Annals of Neurology|2003|485
Mitral valve disease—morphology and mechanisms
|Nature Reviews Cardiology|2015|387